NRAS and Miyoshi myopathy: In the current study, we aimed to provide insight to the individualized anti-EGFR regime in MM by in silico analysis the Genomics of Drug Sensitivity in Cancer (GDSC), and test our hypothesis that solely KRAS/NRAS/BRAF triple-wildtype (WT) subjects could primarily benefit from anti-EGFR treatment.